Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01, FiscalAI reports.

Eledon Pharmaceuticals Price Performance

Shares of Eledon Pharmaceuticals stock traded down $0.25 during trading hours on Friday, hitting $2.12. The company had a trading volume of 1,510,708 shares, compared to its average volume of 908,634. The company’s 50-day moving average is $2.56 and its two-hundred day moving average is $3.11. Eledon Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.49. The company has a market cap of $172.27 million, a P/E ratio of -2.90 and a beta of 0.95.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ELDN shares. Weiss Ratings upgraded Eledon Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, November 9th. Rodman & Renshaw initiated coverage on Eledon Pharmaceuticals in a research report on Tuesday, July 21st. They set a “buy” rating and a $12.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Eledon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eledon Pharmaceuticals presently has an average rating of “Hold” and an average target price of $10.00.

Read Our Latest Stock Report on ELDN

About Eledon Pharmaceuticals

(Get Free Report)

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS). Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS.

Read More

Earnings History for Eledon Pharmaceuticals (NASDAQ:ELDN)

Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.